Adam Feuersteins comments on AEGR at the JP Morgan conference
The tale of two ultra-orphan drug launches: Aegerion Pharmaceuticals (AEGR_) is going to do well with Juxtapid in homozygous familial hypercholesterolemia (HoFH). CEO Marc Beer's presentation was one of the best and most convincing I saw during my three days in San Francisco.